Conference call scheduled for 1:30 p.m. (Pacific); simultaneous
webcast at www.adventrx.com SAN DIEGO, Aug. 2
/PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX)
a biopharmaceutical research and development company focused on
commercializing proprietary product candidates for the treatment of
cancer and infectious diseases, today announced financial results
for the three-month and six-month periods ended June 30, 2007.
Second Quarter 2007 Operating Results ADVENTRX's net loss was $5.7
million, or $0.06 per share, for the three-month period ended June
30, 2007, compared to a net loss of $15.2 million, or $0.21 per
share, for the same period in 2006. Included in the loss for the
three-month period ended June 30, 2007 was non-cash, share-based
compensation expense amounting to $622,000, compared to $356,000
for the same period a year ago. Included in the loss for the
three-month period ended June 30, 2006 was $10.4 million of
in-process research and development expense recorded in connection
with the acquisition of SD Pharmaceuticals and eight of its product
candidates. "The Company's progress in the first half of the year
has now set the stage for several important milestones," stated
Evan M. Levine, chief executive officer of ADVENTRX. "Key upcoming
events in the second half of the year include Phase 2b clinical
trial results for CoFactor, pivotal study results for ANX-530 and
the planned initiation of a clinical study of ANX-201." Research
and development, or R&D, expenses increased by $1.0 million, or
31%, to $4.2 million for the three-month period ended June 30, 2007
from $3.2 million for the same period a year ago. The increase in
R&D expenses was primarily due to a $485,000 increase in
external clinical development costs for ANX-510, or CoFactor(R),
and ANX-530 (vinorelbine emulsion), and a $463,000 increase in
R&D personnel and related costs. R&D expenses for the
three-month period ended June 30, 2007 included non-cash,
share-based compensation expense amounting to $250,000, compared to
$124,000 for the same period a year ago. Selling, general and
administrative, or SG&A, expenses increased by $252,000, or
14%, to $2.0 million for the three-month period ended June 30, 2007
from $1.8 million for the same period a year ago. The increase in
SG&A expenses was primarily due to a $349,000 increase in
SG&A personnel and related costs; partially offset by a
$235,000 decrease in patent-related legal fees. SG&A expenses
for the three-month period ended June 30, 2007 included non-cash,
share-based compensation expense amounting to $372,000, compared to
$232,000 for the same period a year ago. Interest income amounted
to $576,000 for the three-month period ended June 30, 2007,
compared to $252,000 for the same period a year ago. Effective
January 1, 2007, the Company adopted FASB Staff Position on No.
EITF 00-19-2, Accounting for Registration Payment Arrangements, or
FSP EITF 00-19-2. Pursuant to FSP EITF 00-19-2, the Company
determined that no contingent liability was required to be
recognized as of June 30, 2007 relating to a class of warrants
issued in July 2005 that contained a registration payment
arrangement, and accordingly, the carrying amount of the warrant
liability that had been reported in previous periods was
eliminated. In applying the new method retrospectively, the
comparative financial statements of prior periods have been
adjusted to eliminate the fair value of the warrant liability.
Balance Sheet Highlights As of June 30, 2007, the Company had cash,
cash equivalents and investments in securities totaling $43.7
million, including cash and cash equivalents of $16.7 million and
short-term investments in securities of $27.0 million.
Stockholders' equity amounted to $40.8 million as of June 30, 2007.
First Half 2007 Operating Results The net loss for the first six
months of 2007 was $10.8 million, or $0.12 per share, compared to
$19.2 million, or $0.28 per share, for the same period a year ago.
Included in the loss for the first six months of 2006 was $10.4
million of in-process research and development expense recorded in
connection with the acquisition of SD Pharmaceuticals. R&D
expenses were $7.6 million for the first six months of 2007,
compared to $5.7 million for the same period a year ago. The
increase in R&D expenses for 2007 was primarily related to a
$968,000 increase in R&D personnel and related costs, a
$486,000 increase in external clinical study fees and expenses
related to CoFactor and ANX-530, and a $452,000 increase in
external preclinical study fees and expenses mostly related to
ANX-201 (thiophosphonoformate). SG&A expenses were $4.8 million
for the first six months of 2007, compared to $3.5 million for the
same period a year ago. The increase in SG&A expenses for 2007
was primarily related to a $960,000 increase in SG&A personnel
and related costs and a $125,000 increase in professional and
consulting fees related to market research for our product
candidates and investor relations. Revenue of $500,000 in the first
six months of 2007 represented a license fee earned from licensing
ANX-211 (chitosan gel), compared to no revenue for the comparable
period in 2006. Conference Call and Webcast Management will host a
conference call with a simultaneous webcast that will take place on
Thursday, August 2 at 1:30 P.M. Pacific/4:30 P.M. Eastern to
discuss the second quarter of 2007. Evan M. Levine, Chief Executive
Officer, and Gregory P. Hanson, Senior Vice President and Chief
Financial Officer, are scheduled to lead the call and will be
joined by other members of the Company's senior management team.
The webcast will be available live via the Internet by accessing
ADVENTRX's web site at http://www.adventrx.com/ under "Investors"
or by telephone at (877) 704-5386 (domestic) or (913) 312-1302
(international). Replays of the webcast will be available for 30
days, and a phone replay will be available through September 2,
2007 by dialing 888-203-1112 and entering the passcode 7724051.
About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a
biopharmaceutical research and development company focused on
commercializing proprietary product candidates for the treatment of
cancer and infectious diseases. The Company seeks to improve the
performance and safety of existing treatments by addressing
significant problems, such as drug metabolism and bioavailability,
excessive toxicity and treatment resistance. The Company's lead
product candidate CoFactor, is in Phase 3 and Phase 2b clinical
trials for the treatment of metastatic colorectal cancer, as well
as in a Phase 2 clinical trial for the treatment of advanced breast
cancer. More information can be found on ADVENTRX's web site at
http://www.adventrx.com/. Forward Looking Statements ADVENTRX
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they
materialize or do not prove to be accurate, could cause ADVENTRX's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: the risk
that ADVENTRX will be unable to raise sufficient capital to fund
the projects necessary to meet its anticipated or stated goals and
milestones; the ability to timely enroll subjects in ADVENTRX's
current and anticipated clinical trials; the timing and success of
clinical trials; the potential for CoFactor and ADVENTRX's other
product candidates to receive regulatory approval for one or more
indications on a timely basis or at all; the uncertain process of
seeking regulatory approval; other difficulties or delays in
developing, testing, manufacturing and marketing of CoFactor and
ADVENTRX's other product candidates; the potential for regulatory
authorities to require additional preclinical work or other
clinical requirements to support regulatory filings; the scope and
validity of patent protection for CoFactor and ADVENTRX's other
product candidates; adverse side effects or inadequate therapeutic
efficacy of CoFactor or ADVENTRX's other product candidates; the
risk that preclinical results are not indicative of the success of
subsequent clinical trials and that products will not perform as
preclinical and clinical data suggest or as otherwise anticipated;
and other risks and uncertainties more fully described in
ADVENTRX's press releases and periodic filings with the Securities
and Exchange Commission. ADVENTRX's public filings with the
Securities and Exchange Commission are available at
http://www.sec.gov/. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date when made. ADVENTRX does not intend to update any
forward-looking statement, including as set forth in this press
release, to reflect events or circumstances arising after the date
on which it was made. ADVENTRX Pharmaceuticals, Inc. and
Subsidiaries (A Development Stage Enterprise) Summary Condensed
Consolidated Financial Information (In 000s except for per share
data) Consolidated Statement of Operations Data: Quarters Ended
June 30, Six Months Ended June 30 2007 2006 2007 2006 (Unaudited)
(Unaudited) (Unaudited) (Unaudited) Revenues $ -- $ -- $500 $ --
Operating expenses: Research and development 4,240 3,234 7,624
5,718 Selling, general and administrative 2,006 1,755 4,816 3,490
Depreciation and amortization 53 41 105 78 In-process research and
development -- 10,422 -- 10,422 Total operating expenses 6,299
15,452 12,545 19,708 Loss from operations (6,299) (15,452) (12,045)
(19,708) Interest income 576 252 1,198 489 Loss before income taxes
(5,723) (15,200) (10,847) (19,219) Provision for income taxes -- --
-- -- Net loss $(5,723) $(15,200) $(10,847) $(19,219) Net loss per
share - basic and diluted $(0.06) $(0.21) $(0.12) $(0.28) Weighted
average shares - basic and diluted 89,707 71,215 89,692 69,604
Balance Sheet Data: June 30, December 31, 2007 2006 (Unaudited)
Total cash and investments in securities $43,719 $51,745 Net
working capital 40,354 49,889 Total assets 44,945 52,798 Total
liabilities 4,189 2,484 Stockholders' equity 40,757 50,314
DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Investors,
Ioana C. Hone of ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866
Web site: http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024